失调
肠道菌群
纤维化
脂肪肝
肝星状细胞
医学
慢性肝病
氧化应激
肝纤维化
肝纤维化
肝病
肝损伤
药理学
免疫学
化学
肝癌
非酒精性脂肪肝
癌症研究
内科学
肝硬化
生物
磷酰胆碱
作者
Jisu Kim,Yejin Sim,Dong-Ha Kim,Jaehee Kwon,Sanghoon Lee,Wiramon Rungratanawanich,Jihoon Kim,Jinsun Jung,Yongyook Lee,Sunhee Hyun,Seungho Lee,Hyojung Kwon,Byoungjoon Song,Kwangwon Seo,Dokyun Kim,Youngeun Cho
标识
DOI:10.1016/j.ajps.2025.101105
摘要
Metabolic dysfunction-associated fatty liver disease (MASLD) and alcohol-associated liver disease (ALD) are prevalent chronic liver diseases that can progress to steatohepatitis, fibrosis, cirrhosis, and ultimately liver failure. Here, we demonstrated that oral administration of GNVs provided substantial protection against liver injury and fibrosis in MASLD and ALD mouse models. In a Western-style high-fat diet-induced MASLD model and a chronic binge alcohol-induced ALD model, GNVs treatment significantly reduced gut leakiness by restoring intestinal junctional complex proteins and rebalancing the gut microbiome. GNVs attenuated hepatic lipid accumulation, oxidative stress and fibrogenic markers. GNV treatment downregulated the fibrosis-associated tissue inhibitor of metalloproteinase-2 (TIMP2) pathway in hepatic stellate cells, which is linked to enhanced matrix degradation and reduced fibrogenesis. GNVs prevent MASLD- and ALD-associated gut barrier dysfunction and liver fibrosis through modulation of the gut-liver axis and the TIMP2 pathway. Edible GNVs represent a novel, multifaceted therapeutic strategy for managing chronic liver diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI